Johnson & Johnson Earnings: Resilience Meets Valuation Considerations

# Johnson & Johnson Stock Analysis: Q1 2024 Earnings Preview & Investment Outlook Discover the latest financial insights on Johnson & Johnson (JNJ) as the healthcare giant prepares to release its quarterly earnings report. With shares trading near $190, outperforming the S&P 500 by 6+ percentage points over the past year, investors are closely watching this pharmaceutical powerhouse. This episode breaks down JNJ's current market position, analyst expectations of $2.76 EPS, and what the company's post-Kenvue strategy means for your investment portfolio. Learn why institutional investors now control 69% of shares and major banks like Citigroup have raised price targets above $210. Perfect for healthcare investors seeking to understand JNJ's valuation metrics, dividend outlook, and growth potential in innovative medicines and medical technology sectors. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.